Clinical Drug Investigation

, Volume 22, Issue 6, pp 347–354

Effect of Metformin on Blood Pressure

A Study in Obese Non-Diabetic Patients with Hypertension
  • Ilkka Kantola
  • Juha Rouru
  • Kimmo Malminiemi
  • Perttu Arkkila
  • Krista Korhonen
  • Sirpa Rantanen
  • Risto Huupponen
Original Research Article

Abstract

Objective: To evaluate the effect of metformin on blood pressure and insulin sensitivity in non-diabetic, moderately obese, hypertensive patients.

Patients and methods: An 8-week double-blind, placebo-controlled randomised study with a 4-week placebo run-in period was performed. Euglycaemic hyperinsulinaemic clamp tests and 24-hour ambulatory blood pressure measurements were performed after the 4-week placebo run-in period and after the 8-week double-blind treatment in patients in either the metformin 1500mg a day (n = 11) or corresponding placebo (n = 10) group.

Results: Metformin administration did not decrease either 24-hour ambulatory or office blood pressure when compared with placebo. The office mean systolic/ diastolic (±standard deviation) blood pressures before and after treatments were 153 (±22)/96 (±4)mm Hg and 155 (±14)/94 (+6)mm Hg in the metformin group, and 153 (±30)/97 (± 9)mm Hg and 149 (± 18)/96 (± 9)mm Hg in the placebo group, respectively. Metformin significantly decreased fasting serum glucose concentrations from 5.7 (± 0.9) to 5.2 (± 0.4) mmol/L (p = 0.04), but did not affect the insulin sensitivity of the patients.

Conclusions: Metformin does not appear to have a place in the treatment of hypertension in non-diabetic individuals, at least in those with mild hypertension.

References

  1. 1.
    Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrannini EF, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol 1990; 15 Suppl. 5: S18–25PubMedGoogle Scholar
  3. 3.
    Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203–9PubMedCrossRefGoogle Scholar
  4. 4.
    Berntorp K, Lindgärd F, Mattiasson I. Long-term effects on insulin sensitivity and sodium transport in glucose-intolerant hypertensive subjects when β-blockade is replaced by captopril treatment. J Hum Hypertens 1992; 6: 291–8PubMedGoogle Scholar
  5. 5.
    Schafer G. Biguanides: a review of history, pharmacodynamics and therapy. Diabetes Metab 1983; 9: 148–63Google Scholar
  6. 6.
    Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755–72PubMedCrossRefGoogle Scholar
  7. 7.
    DeFronzo RA, Goodman AM, the Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541–9PubMedCrossRefGoogle Scholar
  8. 8.
    Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62–7PubMedCrossRefGoogle Scholar
  9. 9.
    DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294–301PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42: 1217–22PubMedCrossRefGoogle Scholar
  11. 11.
    Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920–8PubMedCrossRefGoogle Scholar
  12. 12.
    Hother-Nielsen O, Schmitz O, Andersen PH, et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 1989; 120: 257–65Google Scholar
  13. 13.
    Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1998; 13: 696–704CrossRefGoogle Scholar
  14. 14.
    Widen EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41: 354–8PubMedCrossRefGoogle Scholar
  15. 15.
    Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181–7PubMedCrossRefGoogle Scholar
  16. 16.
    Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994; 235: 335–41PubMedCrossRefGoogle Scholar
  17. 17.
    Giugliano D, DeRosa N, DiMaro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387–90PubMedCrossRefGoogle Scholar
  18. 18.
    Snorgaard O, Koeber L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242: 407–12PubMedCrossRefGoogle Scholar
  19. 19.
    O’Brien E, Atkins N, Mee F, et al. Comparative accuracy of six ambulatory devices according to blood pressure levels. J Hypertens 1993; 11: 673–5PubMedCrossRefGoogle Scholar
  20. 20.
    De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–23Google Scholar
  21. 21.
    Yki-Järvinen H. Action of insulin on glucose metabolism in vivo. Bailliere’s Clin Endocrinol Metab 1993; 7: 903–28CrossRefGoogle Scholar
  22. 22.
    Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–54PubMedCrossRefGoogle Scholar
  23. 23.
    Uehara MH, Kohlmann NE, Zanella MT, et al. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001; 3: 319–25PubMedCrossRefGoogle Scholar
  24. 24.
    Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991; 14 Suppl. 4: 39–47PubMedGoogle Scholar
  25. 25.
    DeFronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94PubMedCrossRefGoogle Scholar
  26. 26.
    Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–9PubMedCrossRefGoogle Scholar
  27. 27.
    Starke AAR. Determination of insulin sensitivity: methodological considerations. Cardiovasc Pharmacol 1992; 20 Suppl. 11: S17–21CrossRefGoogle Scholar
  28. 28.
    Boden G, Chen X, DeSantis RA, et al. Effects of age and body fat on insulin resistance in healthy men. Diabetes Care 1993; 16: 728–33PubMedCrossRefGoogle Scholar
  29. 29.
    Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994; 78: 25–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Ilkka Kantola
    • 1
  • Juha Rouru
    • 2
  • Kimmo Malminiemi
    • 3
  • Perttu Arkkila
    • 4
  • Krista Korhonen
    • 5
  • Sirpa Rantanen
    • 5
  • Risto Huupponen
    • 2
  1. 1.Department of MedicineTurku University Central HospitalTurkuFinland
  2. 2.Department of Pharmacology and Clinical PharmacologyUniversity of TurkuTurkuFinland
  3. 3.Department of MedicineTampere University HospitalTampereFinland
  4. 4.Department of MedicineHelsinki University Central HospitalHelsinkiFinland
  5. 5.Härkätie Health CentreLietoFinland

Personalised recommendations